Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 2/20 | 0.49 |
| ▸ | EBP | Q15125 | 8/20 | 0.46 |
| ▸ | PRKAG1 | P54619 | 10/20 | 0.41 |
| ▸ | PRKAA2 | P54646 | 10/20 | 0.41 |
| ▸ | PRKAB1 | Q9Y478 | 10/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20003472 | 0.91 | PRKAG1 (0.50) | HMGCRPRKAG1PRKAA2PRKAB1 | |
| SCHEMBL17597866 | 0.86 | NR1H3 (0.38) | HMGCRPRKAG1PRKAA2PRKAB1 | |
| SCHEMBL20553014 | 0.85 | HMGCR (0.48) | HMGCREBPPRKAG1PRKAA2PRKAB1 | |
| SCHEMBL17597110 | 0.85 | PRKAG1 (0.53) | HMGCRPRKAG1PRKAA2PRKAB1 | |
| SCHEMBL15776448 | 0.84 | PRKAG1 (0.55) | HMGCRPRKAG1PRKAA2PRKAB1 | |
| SCHEMBL16533990 | 0.84 | HMGCR (0.45) | HMGCREBPPRKAG1PRKAA2PRKAB1 | |
| SCHEMBL23795763 | 0.84 | HMGCR (0.47) | HMGCREBPPRKAG1PRKAA2PRKAB1 | |
| SCHEMBL20552574 | 0.82 | HMGCR (0.50) | HMGCREBPPRKAG1PRKAA2PRKAB1 | |
| SCHEMBL1525597 | 0.81 | HMGCR (0.47) | HMGCREBPPRKAG1PRKAA2PRKAB1 | |
| SCHEMBL4957748 | 0.79 | HMGCR (0.55) | HMGCREBPPRKAG1PRKAA2PRKAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 308 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3877519-B1 | BIOSYNTHESIS OF MOGROSIDES | GINKGO BIOWORKS INC (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4698673-A1 | STRAINS AND METHODS FOR THE PRODUCTION OF MOGROSIDES | DSM IP Assets B.V. (NL) | 2026-02-25 | — | — | EP | claimed |
| WO-2025101625-A1 | ENZYMES, HOST CELLS, AND METHODS FOR PRODUCING MOGROSIDES | MANUS BIO INC. (US) | 2025-05-15 | — | — | WO | claimed |
| US-12286661-B2 | Methods for making high intensity sweeteners | FIRMENICH INCORPORATED (US) | 2025-04-29 | — | — | US | claimed |
| US-12234464-B2 | Biosynthesis of mogrosides | GINKGO BIOWORKS, INC. (US) | 2025-02-25 | — | — | US | claimed |
| CN-113302298-B | Biosynthesis of mogrosides | 银杏生物制品公司 | 2025-02-25 | — | — | CN | claimed |
| CN-119410506-A | Recombinant yeast engineering strain for producing cucurbitadienol and application thereof | 江南大学 | 2025-02-11 | — | — | CN | claimed |
| CN-119242624-A | Cucurbitadienol synthase mutant and application thereof | 生合万物(上海)生物科技有限公司 | 2025-01-03 | — | — | CN | claimed |
| CN-111108213-B | Method for preparing high intensity sweetener | 弗门尼舍公司 | 2024-12-13 | — | — | CN | claimed |
| WO-2024218244-A1 | STRAINS AND METHODS FOR THE PRODUCTION OF MOGROSIDES | DSM IP ASSETS B.V. (NL) | 2024-10-24 | — | — | WO | claimed |
| US-20180251806-A1 | Methods and Materials for Biosynthesis of Mogroside Compounds | DANSTAR FERMENT AG (CH) | 2018-09-06 | — | — | US | claimed |
| US-10011859-B2 | Methods and materials for biosynthesis of mogroside compounds | EVOLVA SA (CH) | 2018-07-03 | — | — | US | claimed |
| US-9932619-B2 | Methods and materials for biosynthesis of mogroside compounds | EVOLVA SA (CH) | 2018-04-03 | — | — | US | claimed |
| US-20170247735-A1 | Methods and Materials for Biosynthesis of Mogroside Compounds | DANSTAR FERMENT AG (CH) | 2017-08-31 | — | — | US | claimed |
| EP-3201315-A2 | METHODS AND MATERIALS FOR BIOSYNTHESIS OF MOGROSIDE COMPOUNDS | Evolva SA (CH) | 2017-08-09 | — | — | EP | claimed |
| US-20150322473-A1 | Methods and materials for Biosynthesis of Mogroside Compounds | DANSTAR FERMENT AG (CH) | 2015-11-12 | — | — | US | claimed |
| EP-2929043-A1 | METHODS AND MATERIALS FOR BIOSYNTHESIS OF MOGROSIDE COMPOUNDS | Evolva SA (CH) | 2015-10-14 | — | — | EP | claimed |
| WO-2014086842-A9 | METHODS AND MATERIALS FOR BIOSYNTHESIS OF MOGROSIDE COMPOUNDS | EVOLVA SA (CH) | 2015-06-18 | — | — | WO | claimed |
| US-20150064743-A1 | Methods and Materials for Biosynthesis of Mogroside Compounds | DANSTAR FERMENT AG (CH) | 2015-03-05 | — | — | US | claimed |
| WO-2014086842-A1 | METHODS AND MATERIALS FOR BIOSYNTHESIS OF MOGROSIDE COMPOUNDS | EVOLVA SA (CH) | 2014-06-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247735-A1 | Methods and Materials for Biosynthesis of Mogroside Compounds | DCXR, COASY, MOGAT2 | HMGCR 170/4885EBP 1394/4885PRKAG1 3391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.